Sorry, you need to enable JavaScript to visit this website.
Skip to main content


Newman Yeilding, M.D.

Newman Yeilding, MD



Newman Yeilding, M.D. is Head of Development, Immunology at Janssen Research & Development, LLC. In this position, he is responsible for providing scientific and management leadership of global development initiatives and investments. This includes overseeing all programs supporting new molecular entities in rheumatologic/maternal-fetal, gastrointestinal, and dermatologic diseases, and the IL-23 and autoantibody pathway areas, as well as life cycle indications for the industry-leading Janssen Immunology portfolio.

Newman joined the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor in 2002 where he served in various roles of increasing responsibility in Medical Affairs and Immunology Development. Most notably, he was instrumental in the development and approval of one of the company’s leading biologics, which he has continued to oversee through new indications in dermatology and gastroenterology. Newman has more than 25 years of clinical and research experience and has contributed to more than 30 scientific publications.

Newman earned his medical degree from the University of Alabama School of Medicine and completed his residency training in internal medicine at the Hospital of the University of Pennsylvania. He completed sub-specialty training in hematology and medical oncology and in 1995 joined the faculty at the University of Pennsylvania, where he practiced and ran a research lab focused on molecular oncology.

Follow Newman on LinkedIn here.